Novavax, Inc. (LON:0A3S)

Market Cap	1.01B
Revenue (ttm)	660.44M
Net Income (ttm)	-212.53M
Shares Out	n/a
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,478
Average Volume	53,516
Open	8.06
Previous Close	7.84
Day's Range	7.77 - 8.05
52-Week Range	2.82 - 21.57
Beta	2.13
RSI	47.40
Earnings Date	Feb 28, 2025

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 1,543
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3S

Financial Performance

In 2023, Novavax's revenue was $983.71 million, a decrease of -50.36% compared to the previous year's $1.98 billion. Losses were -$545.06 million, -17.16% less than in 2022.

Financial numbers in USD